Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme reacquires Synvisc rights

This article was originally published in The Gray Sheet

Executive Summary

Genzyme will pay Wyeth $121 mil. up-front, plus up to $294 mil. in milestones by 2012 to buy back marketing rights to the hyaluronic acid-based knee osteoarthritis treatment for the U.S. and certain European countries. Genzyme, which already markets Synvisc in the UK, France, Canada and Australia, estimates worldwide Synvisc sales at $240 mil. for 2004. The firm plans to combine Wyeth's 105-person dedicated U.S. sales force with its own 36-person U.S. team marketing Synvisc and Carticel autologous cultured chondrocytes for knee cartilage repair, extending its orthopedic market reach. Synvisc currently controls 65% of the U.S. viscosupplementation market. A U.S. hip trial is under way. Approved in the U.S. for knees in August 1997, Synvisc developer Biomatrix was acquired by Genzyme's Biosurgery division in 2000 (1"The Gray Sheet" March 13, 2000, p. 16)...

You may also be interested in...



Synvisc OA Therapy Boosts Margins, Holds Promise For New Indications

Genzyme's recent reacquisition of marketing rights to the Synvisc knee osteoarthritis treatment will help the firm realize a hefty gross margins increase in 2005

Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix

Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

UsernamePublicRestriction

Register

MT021140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel